15000 results for "cancer studies using rna-seq"

in 25.92 milliseconds.

• CAGEKID: Cancer Genomics of the Kidney

  Study EGAS00001000083

• Extreme intratumor heterogeneity and driver evolution in mismatch repair deficient gastro-esophageal cancer

  Study EGAS00001003434

• Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells

  Study EGAS00001007026

• Pan Prostate Cancer Group Data Access Control Committee

  DACC for the PanProstate Cancer Group projects

  Dac EGAC50000000602

• APOBEC3 mutagenesis drives therapy resistance in breast cancer

  Acquired genetic alterations commonly drive resistance to endocrine and targeted therapies in metastatic breast cancer, however the underlying processes engendering these diverse alterations are largely uncharacterized. To identify the mutational processes operant in breast cancer and their impact on clinical outcomes, we utilized a well-annotated cohort of 3,880 patient samples with paired tumor-normal sequencing data. The mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) enzymes were highly prevalent and enriched in post-treatment compared to treatment-naïve hormone receptor-positive (HR+) cancers. APOBEC3 mutational signatures were independently associated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor combination therapy in patients with HR+ metastatic breast cancer. Whole genome sequencing (WGS) of breast cancer models and selected paired primary-metastatic samples demonstrated that active APOBEC3 mutagenesis promoted resistance to both endocrine and targeted therapies through characteristic alterations such as RB1 loss-of-function mutations. Evidence of APOBEC3 activity in pre-treatment samples illustrated a pervasive role for this mutational process in breast cancer evolution. The study reveals APOBEC3 mutagenesis to be a frequent mediator of therapy resistance in breast cancer and highlights its potential as a biomarker and target for overcoming resistance.

  Study EGAS50000000875

• Proteogenomic discovery of a novel class of cancer antigens by HLA ligandome analysis of colon cancer tissues

  CD8+ T cells recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathological conditions such as cancer. Recent advances in proteogenomic analysis of HLA ligandomes have demonstrated that cells present a subset of cryptic peptides derived from non-coding regions of the genome; however, the roles of cryptic HLA ligands in tumor immunity remain unknown. In the present study, we comprehensively and quantitatively investigated the HLA class I ligandome of a set of human colorectal cancer (CRC) and matched normal tissues, showing that cryptic translation products account for a small fraction of the HLA class I ligandome and serve as antigens for patient T cell surveillance against colon cancer.

  Study JGAS000280

• 10X single-nuclei RNA sequencing

  Single-nuclei sequencing data from four neuroblastoma patients. Each patient was run on two lanes, resulting in two runs per patient. Data is provided in paired-end fastq files.

  Dataset EGAD50000000727

• Long-read RNA sequencing of human normal liver organoid with or without SF3B4 overexpression

  Project aims to find alternative splicing events and resulting transcript isoforms modulated by SF3B4

  Study EGAS50000000849

• Hypoxia and plasma treatment of glioblastoma organoids

  RNA sequencing of organoids derived from human glioblastoma subject to hypoxia, plasma, or a combination of both for 72h, sampled at 0, 24, 72, and 144h.

  Dataset EGAD50000002081

• PDX RNA

  RNAseq from PDX tumours under treatment with dpbs or eribulin. Sarcomatous or mixed sarcoma/carcinoma. 6 PDX tumours each with 2 treatments gave 12 pairs of fastq files.

  Dataset EGAD00001009658

• Gene expression associated with Klinefelter syndrome

  RNA-sequencing profiling of leucocytes from peripheral blood samples from 9 KS patients, 9 control males and 13 female controls

  Dataset EGAD00001010078

• Whole blood Transcriptome of patients with ANCA-associated vasculitis

  This dataset contains RNA-sequencing of whole blood samples from Healthy Controls (n=11), AAV patients (n=30, GPAn=22, MPAn=8).

  Dataset EGAD00001009792

• RNA sequencing of undifferentiated sarcomas

  mRNA sequencing of 50 undifferentiated sarcoma tumour samples and 5 adjacent muscle tissue samples. BAM files are provided, with metadata specifying which samples are tumour/normal.

  Dataset EGAD00001004439

• Single cell sequencing in CNS autoimmune disease

  RNA, T cell receptor and B cell receptor single cell sequencing data generated on T and B cells derived from patients with CNS autoimmune disease

  Dataset EGAD00001006232

• Microdissected Pancreatic Cancer Whole Exome Sequencing

  109 micro-dissected pancreatic cancer cases and normal control tissue were subjected to whole-exome sequencing. Microdissection enriches tumor cellularity and enhances mutation calling.

  Study phs000953

• Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer

  Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.

  Study phs000980

• TOTHER3

  Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI TOT-HER3 trial and biological determinants of early response

  Study EGAS50000000385

• Low-coverage whole genome sequencing of plasma from BRCA-mutant breast cancer patients

  Plasma samples from patients with breast cancer (stage IV) who had confirmed BRCA mutations were subjected to low-coverage whole-genome sequencing This dataset contains raw fastq files from 6 breast cancer plasma samples.

  Dataset EGAD50000000810

• HiSeq Colorectal Cancer Dataset

  Set of 19 patients afflicted with colorectal cancer with matching preoperative and postoperative blood plasma, PBMC, and tumor biopsy sequencing data. Originally referenced by Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020, Zviran et. al.

  Dataset EGAD00001011186